

RECEIVED

JUN 04 2003

TECH CENTER 1600/2000

1600

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,567

DATE: 05/27/2003

TIME: 09:04:18

Input Set : A:\015270-005911US.APP

Output Set: N:\CRF4\05272003\I724567.raw

3 <110> APPLICANT: Schenk, Dale B.  
 4 Elan Pharmaceuticals  
 6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Diseases  
 8 <130> FILE REFERENCE: 015270-005911US  
 10 <140> CURRENT APPLICATION NUMBER: US 09/724,567  
 11 <141> CURRENT FILING DATE: 2000-11-28  
 13 <150> PRIOR APPLICATION NUMBER: WO PCT/US00/25239  
 14 <151> PRIOR FILING DATE: 2000-06-01  
 16 <150> PRIOR APPLICATION NUMBER: US 60/137,010  
 17 <151> PRIOR FILING DATE: 1999-06-01  
 19 <160> NUMBER OF SEQ ID NOS: 34  
 21 <170> SOFTWARE: PatentIn Ver. 2.1  
 23 <210> SEQ ID NO: 1  
 24 <211> LENGTH: 13  
 25 <212> TYPE: PRT  
 26 <213> ORGANISM: Artificial Sequence  
 28 <220> FEATURE:  
 29 <223> OTHER INFORMATION: Description of Artificial Sequence:influenza  
 30 hemagglutinin HA 307-319 universal T-cell epitope  
 32 <400> SEQUENCE: 1  
 33 Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr  
 34 1 5 10  
 37 <210> SEQ ID NO: 2  
 38 <211> LENGTH: 13  
 39 <212> TYPE: PRT  
 40 <213> ORGANISM: Artificial Sequence  
 42 <220> FEATURE:  
 43 <223> OTHER INFORMATION: Description of Artificial Sequence:PADRE universal  
 44 T-cell epitope  
 46 <220> FEATURE:  
 47 <221> NAME/KEY: MOD\_RES  
 48 <222> LOCATION: (3)  
 49 <223> OTHER INFORMATION: Xaa = any amino acid  
 51 <400> SEQUENCE: 2  
 W--> 52 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala  
 53 1 5 10  
 56 <210> SEQ ID NO: 3  
 57 <211> LENGTH: 16  
 58 <212> TYPE: PRT  
 59 <213> ORGANISM: Artificial Sequence  
 61 <220> FEATURE:  
 62 <223> OTHER INFORMATION: Description of Artificial Sequence:malaria CS T3  
 63 epitope universal T-cell epitope

ENTERED

## RAW SEQUENCE LISTING

DATE: 05/27/2003

PATENT APPLICATION: US/09/724,567

TIME: 09:04:18

Input Set : A:\015270-005911US.APP

Output Set: N:\CRF4\05272003\I724567.raw

```

65 <400> SEQUENCE: 3
66 Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val
67   1             5             10             15
70 <210> SEQ ID NO: 4
71 <211> LENGTH: 10
72 <212> TYPE: PRT
73 <213> ORGANISM: Artificial Sequence
75 <220> FEATURE:
76 <223> OTHER INFORMATION: Description of Artificial Sequence:Hepatitis B
77     surface antigen HBsAg 19-28 universal T-cell
78     epitope
80 <400> SEQUENCE: 4
81 Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
82   1             5             10
85 <210> SEQ ID NO: 5
86 <211> LENGTH: 19
87 <212> TYPE: PRT
88 <213> ORGANISM: Artificial Sequence
90 <220> FEATURE:
91 <223> OTHER INFORMATION: Description of Artificial Sequence:heat shock
92     protein 65 hsp65 153-171 universal T-cell epitope
94 <400> SEQUENCE: 5
95 Asp Gln Ser Ile Gly Asp Leu Ile Ala Glu Ala Met Asp Lys Val Gly
96   1             5             10             15
98 Asn Glu Gly
102 <210> SEQ ID NO: 6
103 <211> LENGTH: 14
104 <212> TYPE: PRT
105 <213> ORGANISM: Artificial Sequence
107 <220> FEATURE:
108 <223> OTHER INFORMATION: Description of Artificial Sequence:bacillus
109     Calmette-Guerin universal T-cell epitope
111 <400> SEQUENCE: 6
112 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu
113   1             5             10
116 <210> SEQ ID NO: 7
117 <211> LENGTH: 15
118 <212> TYPE: PRT
119 <213> ORGANISM: Artificial Sequence
121 <220> FEATURE:
122 <223> OTHER INFORMATION: Description of Artificial Sequence:tetanus toxoid
123     TT 830-844 universal T-cell epitope
125 <400> SEQUENCE: 7
126 Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
127   1             5             10             15
130 <210> SEQ ID NO: 8
131 <211> LENGTH: 21
132 <212> TYPE: PRT
133 <213> ORGANISM: Artificial Sequence

```

## RAW SEQUENCE LISTING

DATE: 05/27/2003

PATENT APPLICATION: US/09/724,567

TIME: 09:04:18

Input Set : A:\015270-005911US.APP

Output Set: N:\CRF4\05272003\I724567.raw

```

135 <220> FEATURE:
136 <223> OTHER INFORMATION: Description of Artificial Sequence:tetanus toxoid
137     TT 947-967 universal T-cell epitope
139 <400> SEQUENCE: 8
140 Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
141   1           5           10           15
143 Ala Ser His Leu Glu
144           20
147 <210> SEQ ID NO: 9
148 <211> LENGTH: 16
149 <212> TYPE: PRT
150 <213> ORGANISM: Artificial Sequence
152 <220> FEATURE:
153 <223> OTHER INFORMATION: Description of Artificial Sequence:HIV gp120 T1
154     universal T-cell epitope
156 <400> SEQUENCE: 9
157 Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala
158   1           5           10           15
161 <210> SEQ ID NO: 10
162 <211> LENGTH: 22
163 <212> TYPE: PRT
164 <213> ORGANISM: Artificial Sequence
166 <220> FEATURE:
167 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90549 (Abeta
168     1-7/tetanus toxoid 830-844 in a MAP4
169     configuration)
171 <400> SEQUENCE: 10
172 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
173   1           5           10           15
175 Ile Gly Ile Thr Glu Leu
176           20
179 <210> SEQ ID NO: 11
180 <211> LENGTH: 28
181 <212> TYPE: PRT
182 <213> ORGANISM: Artificial Sequence
184 <220> FEATURE:
185 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90550 (Abeta
186     1-7/tetanus toxoid 947-967 in a MAP4
187     configuration)
189 <400> SEQUENCE: 11
190 Asp Ala Glu Phe Arg His Asp Phe Asn Asn Phe Thr Val Ser Phe Trp
191   1           5           10           15
193 Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu
194           20           25
197 <210> SEQ ID NO: 12
198 <211> LENGTH: 43
199 <212> TYPE: PRT
200 <213> ORGANISM: Artificial Sequence
202 <220> FEATURE:

```

## RAW SEQUENCE LISTING

DATE: 05/27/2003

PATENT APPLICATION: US/09/724,567

TIME: 09:04:18

Input Set : A:\015270-005911US.APP

Output Set: N:\CRF4\05272003\I724567.raw

203 <223> OTHER INFORMATION: Description of Artificial Sequence:AN 90542 (Abeta  
 204 1-7/tetanus toxoid 830-844 + 947-967 in a linear  
 205 configuration)

207 <400> SEQUENCE: 12

208 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe

209 1 5 10 15

211 Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu

212 20 25 30

214 Arg Val Pro Lys Val Ser Ala Ser His Leu Glu

215 35 40

218 <210> SEQ ID NO: 13

219 <211> LENGTH: 22

220 <212> TYPE: PRT

221 <213> ORGANISM: Artificial Sequence

223 <220> FEATURE:

224 <223> OTHER INFORMATION: Description of Artificial Sequence:AN 90576 (Abeta

225 3-9/tetanus toxoid 830-844 in a MAP4

226 configuration)

228 <400> SEQUENCE: 13

229 Glu Phe Arg His Asp Ser Gly Gln Tyr Ile Lys Ala Asn Ser Lys Phe

230 1 5 10 15

232 Ile Gly Ile Thr Glu Leu

233 20

236 <210> SEQ ID NO: 14

237 <211> LENGTH: 20

238 <212> TYPE: PRT

239 <213> ORGANISM: Artificial Sequence

241 <220> FEATURE:

242 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90562 (Abeta

243 1-7/peptide on linear conformation)

245 <220> FEATURE:

246 <221> NAME/KEY: MOD\_RES

247 <222> LOCATION: (3)

248 <223> OTHER INFORMATION: Xaa = any amino acid

250 <400> SEQUENCE: 14

W--> 251 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu

252 1 5 10 15

254 Phe Arg His Asp

255 20

258 <210> SEQ ID NO: 15

259 <211> LENGTH: 34

260 <212> TYPE: PRT

261 <213> ORGANISM: Artificial Sequence

263 <220> FEATURE:

264 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90543 (Abeta

265 1-7 X 3/peptide in linear conformation)

267 <220> FEATURE:

268 <221> NAME/KEY: MOD\_RES

269 <222> LOCATION: (24)

## RAW SEQUENCE LISTING

DATE: 05/27/2003

PATENT APPLICATION: US/09/724,567

TIME: 09:04:18

Input Set : A:\015270-005911US.APP

Output Set: N:\CRF4\05272003\I724567.raw

```

270 <223> OTHER INFORMATION: Xaa = any amino acid
272 <400> SEQUENCE: 15
273 Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala
274   1           5           10           15
W--> 276 Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala
277           20           25           30
279 Ala Ala
283 <210> SEQ ID NO: 16
284 <211> LENGTH: 34
285 <212> TYPE: PRT
286 <213> ORGANISM: Artificial Sequence
288 <220> FEATURE:
289 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein
290     with Abeta immunogenic epitope
292 <220> FEATURE:
293 <221> NAME/KEY: MOD_RES
294 <222> LOCATION: (3)
295 <223> OTHER INFORMATION: Xaa = any amino acid
297 <400> SEQUENCE: 16
W--> 298 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu
299   1           5           10           15
301 Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg
302           20           25           30
304 His Asp
308 <210> SEQ ID NO: 17
309 <211> LENGTH: 20
310 <212> TYPE: PRT
311 <213> ORGANISM: Artificial Sequence
313 <220> FEATURE:
314 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein
315     with Abeta immunogenic epitope
317 <220> FEATURE:
318 <221> NAME/KEY: MOD_RES
319 <222> LOCATION: (10)
320 <223> OTHER INFORMATION: Xaa = any amino acid
322 <400> SEQUENCE: 17
W--> 323 Asp Ala Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu
324   1           5           10           15
326 Lys Ala Ala Ala
327           20
330 <210> SEQ ID NO: 18
331 <211> LENGTH: 24
332 <212> TYPE: PRT
333 <213> ORGANISM: Artificial Sequence
335 <220> FEATURE:
336 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein
337     with Abeta immunogenic epitope
339 <400> SEQUENCE: 18
340 Asp Ala Glu Phe Arg His Asp Ile Ser Gln Ala Val His Ala Ala His

```

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/724,567

DATE: 05/27/2003  
TIME: 09:04:19

Input Set : A:\015270-005911US.APP  
Output Set: N:\CRF4\05272003\I724567.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; Xaa Pos. 3  
Seq#:14; Xaa Pos. 3  
Seq#:15; Xaa Pos. 24  
Seq#:16; Xaa Pos. 3  
Seq#:17; Xaa Pos. 10  
Seq#:32; Xaa Pos. 2  
Seq#:33; Xaa Pos. 1